1. Home
  2. LPSN vs LPCN Comparison

LPSN vs LPCN Comparison

Compare LPSN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$1.86

Market Cap

21.6M

Sector

Technology

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.14

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
LPCN
Founded
1995
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
19.1M
IPO Year
2000
2011

Fundamental Metrics

Financial Performance
Metric
LPSN
LPCN
Price
$1.86
$2.14
Analyst Decision
Hold
Hold
Analyst Count
1
1
Target Price
N/A
N/A
AVG Volume (30 Days)
64.2K
33.7K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
$249,838,000.00
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$1.81
52 Week High
$7.54
$12.37

Technical Indicators

Market Signals
Indicator
LPSN
LPCN
Relative Strength Index (RSI) 51.63 39.89
Support Level $1.80 $1.94
Resistance Level $2.44 $2.50
Average True Range (ATR) 0.09 0.09
MACD 0.02 -0.02
Stochastic Oscillator 90.22 13.95

Price Performance

Historical Comparison
LPSN
LPCN

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: